Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma
This trial is active, not recruiting.
|Treatments||cisplatin, mitomycin c, vinblastine sulfate, vinorelbine tartrate|
|Sponsor||British Thoracic Society|
|Collaborator||Medical Research Council|
|Start date||November 2000|
|Trial identifier||NCT00030459, BTS-MESO-1, CDR0000069167, EU-20134, MRC-BTS-MESO-1|
RATIONALE: Palliative therapy may help patients with advanced cancer live more comfortably. It is not yet known if palliative therapy is more effective with or without chemotherapy in treating patients who have malignant mesothelioma.
PURPOSE: Randomized phase II trial to compare the effectiveness of palliative therapy with or without different chemotherapy regimens in treating patients who have malignant mesothelioma.
|United States||No locations recruiting|
|Other Countries||No locations recruiting|
|Hull, United Kingdom||Princess Royal Hospital||no longer recruiting|
|Leeds, United Kingdom||Leeds Teaching Hospital Trust||no longer recruiting|
|London, United Kingdom||Saint Bartholomew's Hospital||no longer recruiting|
|London, United Kingdom||Medical Research Council Clinical Trials Unit||no longer recruiting|
|Sutton, United Kingdom||Royal Marsden Hospital||no longer recruiting|
|Aberdeen, United Kingdom||Aberdeen Royal Infirmary||no longer recruiting|
|Glasgow, United Kingdom||Stobhill General Hospital||no longer recruiting|
|Bradford-Onavon, United Kingdom||Dorothy House Foundation||no longer recruiting|
|Chertsey Surrey, United Kingdom||St. Peters Hospital||no longer recruiting|
Male or female participants of any age.
DISEASE CHARACTERISTICS: - Immunohistochemically or cytologically confirmed malignant mesothelioma - Epithelial and other histological types - Symptomatic pleural effusion allowed if treated and controlled by drainage, pleurodesis, or pleurectomy - Prior surgical resection allowed if stable or progressive disease by 2 CT scan measurements at least 6 weeks apart PATIENT CHARACTERISTICS: Age: - Not specified Performance status: - WHO 0-2 Life expectancy: - Not specified Hematopoietic: - WBC greater than 3,000/mm3 - Neutrophil count greater than 1,500/mm3 - Platelet count greater than 100,000/mm3 Hepatic: - Not specified Renal: - Not specified Other: - Considered medically fit to receive chemotherapy - No other disease or prior malignancy that would preclude study - No clinical evidence of infection PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - No prior chemotherapy for mesothelioma Endocrine therapy: - Not specified Radiotherapy: - Not specified Surgery: - See Disease Characteristics
|Official title||Randomized Feasibility Study Of Active Symptom Control With Or Without Chemotherapy In The Treatment Of Patients With Mesothelioma|
|Description||OBJECTIVES: - Determine the feasibility of palliative therapy alone versus palliative therapy with mitomycin, vinblastine, and cisplatin versus palliative therapy with vinorelbine in patients with malignant mesothelioma. - Determine the quality of life of patients treated with these regimens. OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of three treatment arms. - Arm I: Patients receive palliative therapy alone comprising non-chemotherapeutic therapy (e.g., radiotherapy, painkillers, steroids, relaxants, and special pain relief techniques). - Arm II: Patients receive palliative therapy as in arm I and chemotherapy comprising mitomycin IV (courses 1, 2, and 4 only), vinblastine IV, and cisplatin IV over 4 hours on day 1. Chemotherapy repeats every 21 days for a total of 4 courses. - Arm III: Patients receive palliative therapy as in arm I and chemotherapy comprising vinorelbine IV over 5 minutes once weekly on weeks 1-6 and 9-14. Quality of life is assessed at baseline for all patients; at weeks 3, 6, 9, and 12 for arm I; at weeks 4, 7, 10, and 13 for arm II; at weeks 3, 6, 10, and 13 for arm III; at weeks 21 and 29, and then every 8 weeks thereafter for all patients. Patients are followed every 8 weeks. PROJECTED ACCRUAL: A total of 60 patients (20 per treatment arm) will be accrued for this study within 1 year.|
Call for more information